{"id":"NCT02008357","sponsor":"Eli Lilly and Company","briefTitle":"Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss","officialTitle":"Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-28","primaryCompletion":"2022-12-27","completion":"2023-06-08","firstPosted":"2013-12-11","resultsPosted":"2023-12-28","lastUpdate":"2023-12-28"},"enrollment":1169,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cognition Disorders"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Solanezumab","otherNames":["LY2062430"]}],"arms":[{"label":"Solanezumab/Solanezumab","type":"EXPERIMENTAL"},{"label":"Placebo/Solanezumab","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \\[AD\\]).","primaryOutcome":{"measure":"Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score","timeFrame":"Baseline, Week approximately 240","effectByArm":[{"arm":"Solanezumab","deltaMin":-1.43,"sd":0.21},{"arm":"Placebo","deltaMin":-1.13,"sd":0.16}],"pValues":[{"comp":"OG000 vs OG001","p":"0.260"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":68,"countries":["United States","Australia","Canada","Japan"]},"refs":{"pmids":["40476544","40440591","37458272","35543002","35197359"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/4qngyPbBRKqiYWCI0ouGIQ"]},"adverseEventsSummary":{"seriousAny":{"events":171,"n":572},"commonTop":["Fall","Upper respiratory tract infection","Arthralgia","Headache","Nasopharyngitis"]}}